Cited 12 times in
Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김은영 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 김한상 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 박무석 | - |
dc.contributor.author | 박지수 | - |
dc.contributor.author | 이준호 | - |
dc.contributor.author | 임선민 | - |
dc.contributor.author | 임승택 | - |
dc.contributor.author | 장준 | - |
dc.contributor.author | 정지예 | - |
dc.contributor.author | 김건민 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 김다래 | - |
dc.contributor.author | 김세규 | - |
dc.contributor.author | 김세현 | - |
dc.contributor.author | 김영삼 | - |
dc.date.accessioned | 2014-12-18T09:00:20Z | - |
dc.date.available | 2014-12-18T09:00:20Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0169-5002 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/87356 | - |
dc.description.abstract | The aim of this study was to investigate the efficacy and safety of belotecan in combination with cisplatin in patients with previously non-treated extensive stage small cell lung cancer. A total of 42 patients were enrolled and treated with combination of belotecan 0.5 mg/m2 on daily basis throughout day 1–4 and cisplatin 60 mg/m2 on day 1 of a 3-week cycle, up to 6 cycles. Treatment was continued until the completion of 6 cycles of the chemotherapy, disease progression, detection of unacceptable toxicity, withdrawal of the consent, or death of the patient. Response was assessed every 2 cycles of chemotherapy by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0. Toxicity was assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 3.0. The overall response rate was 73.8% in an intention to treat population and 83.9% in the evaluable patients. With the median follow up of 9.9 months, the median progression free survival was 6.9 months (95% CI, 6.6–7.2 months), and median overall survival was 11.2 months (95% CI, 9.9–12.5 months). The frequently reported grade ≥ 3 toxicities were neutropenia (90.2%), thrombocytopenia (63.4%), and anemia (34.1%). Febrile neutropenia was reported in 16 patients (39.0%). Although most of non-hematologic toxicities were grade 1 or 2, there were 4 patient deaths caused by pneumonia complicated by septic shock. Belotecan and cisplatin combination chemotherapy demonstrated a promising efficacy in ED SCLC patients. But, the hematologic toxicity of this regimen requires considerable amount of attention. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | LUNG CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/adverse effects | - |
dc.subject.MESH | Camptothecin/analogs & derivatives* | - |
dc.subject.MESH | Cisplatin/administration & dosage* | - |
dc.subject.MESH | Cisplatin/adverse effects | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug-Related Side Effects and Adverse Reactions | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasm Metastasis/drug therapy* | - |
dc.subject.MESH | Neoplasm Metastasis/pathology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Small Cell Lung Carcinoma/drug therapy* | - |
dc.subject.MESH | Small Cell Lung Carcinoma/pathology | - |
dc.subject.MESH | Young Adult | - |
dc.title | Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Seungtaek Lim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Ji Ye Jung | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Se Hyun Kim | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Han Sang Kim | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Ji Soo Park | - |
dc.contributor.googleauthor | Jun Ho Lee | - |
dc.contributor.googleauthor | Darae Kim | - |
dc.contributor.googleauthor | Eun Young Kim | - |
dc.contributor.googleauthor | Moo Suk Park | - |
dc.contributor.googleauthor | Young Sam Kim | - |
dc.contributor.googleauthor | Se Kyu Kim | - |
dc.contributor.googleauthor | Joon Chang | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.identifier.doi | 10.1016/j.lungcan.2013.02.009 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01457 | - |
dc.contributor.localId | A01686 | - |
dc.contributor.localId | A03181 | - |
dc.contributor.localId | A03369 | - |
dc.contributor.localId | A03380 | - |
dc.contributor.localId | A03472 | - |
dc.contributor.localId | A03735 | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A00361 | - |
dc.contributor.localId | A00602 | - |
dc.contributor.localId | A00607 | - |
dc.contributor.localId | A00707 | - |
dc.contributor.localId | A00811 | - |
dc.contributor.localId | A01098 | - |
dc.relation.journalcode | J02174 | - |
dc.identifier.eissn | 1872-8332 | - |
dc.identifier.pmid | 23510628 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0169500213000688 | - |
dc.subject.keyword | Extensive disease | - |
dc.subject.keyword | Small cell lung cancer | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Belotecan | - |
dc.subject.keyword | Cisplatin | - |
dc.subject.keyword | Response | - |
dc.contributor.alternativeName | Kim, Eun Young | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Kim, Han Sang | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Park, Moo Suk | - |
dc.contributor.alternativeName | Park, Ji Soo | - |
dc.contributor.alternativeName | Lee, Jun Ho | - |
dc.contributor.alternativeName | Lim, Sun Min | - |
dc.contributor.alternativeName | Lim, Seung Taek | - |
dc.contributor.alternativeName | Chang, Joon | - |
dc.contributor.alternativeName | Jung, Ji Ye | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Kim, Da Rae | - |
dc.contributor.alternativeName | Kim, Se Kyu | - |
dc.contributor.alternativeName | Kim, Se Hyun | - |
dc.contributor.alternativeName | Kim, Young Sam | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Park, Moo Suk | - |
dc.contributor.affiliatedAuthor | Park, Ji Soo | - |
dc.contributor.affiliatedAuthor | Lee, Jun Ho | - |
dc.contributor.affiliatedAuthor | Lim, Sun Min | - |
dc.contributor.affiliatedAuthor | Lim, Seung Taek | - |
dc.contributor.affiliatedAuthor | Chang, Joon | - |
dc.contributor.affiliatedAuthor | Jung, Ji Ye | - |
dc.contributor.affiliatedAuthor | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Kim, Da Rae | - |
dc.contributor.affiliatedAuthor | Kim, Se Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Se Hyun | - |
dc.contributor.affiliatedAuthor | Kim, Young Sam | - |
dc.contributor.affiliatedAuthor | Kim, Eun Young | - |
dc.contributor.affiliatedAuthor | Kim, Han Sang | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 80 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 313 | - |
dc.citation.endPage | 318 | - |
dc.identifier.bibliographicCitation | LUNG CANCER, Vol.80(3) : 313-318, 2013 | - |
dc.identifier.rimsid | 33000 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.